Clinical Research Directory
Browse clinical research sites, groups, and studies.
Neutralizing Power of Serum Antibodies - 2
Sponsor: Centre Hospitalier Régional d'Orléans
Summary
Severe forms of COVID-19 and Monkeypox affect immunocompromised and comorbid individuals. Vaccination and monoclonal antibody therapies induce neutralizing antibodies. This neutralizing power is recognized as a correlate of protection against a new infection. This study aims to describe the neutralizing power of serum and nasal antibodies over time, in relation to SARS-CoV-2 and MPXV vaccines or treatments received.
Official title: Study of the Neutralizing Power of Serum Antibodies - 2 (PNAS-2)
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
30
Start Date
2025-08-22
Completion Date
2035-07-11
Last Updated
2025-12-19
Healthy Volunteers
No
Interventions
Sample collection (blood and optional nasal swab)
Venous blood collection (2 tubes of 6 mL) and optional nasal swab at each visit. Aliquots analyzed for neutralizing activity against SARS-CoV-2 and MPXV using validated assays at Institut Pasteur
Locations (1)
CHU Orléans
Orléans, France